Pancreatic Cancer Research

ResearcherGifu University HospitalActive in the last 2 years

Ichiro Yasuda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6888-0310; OpenAlex author ID A5041698698, A5124061649. Sources: OpenAlex.

Their work

Papers
23 (first author 4, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2011: 5 papers · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 3 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 10 papers

Papers 23

  1. Development of novel serum peptide biomarkers for screening pancreatic cancer. Co-author DOI 10.1007/s00535-025-02314-z↗
  2. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  3. Third-Line Treatment Timing After Second-Line Discontinuation in Advanced Pancreatic Cancer: A 30-Day Landmark Analysis. Last author DOI 10.1007/s12029-026-01565-0↗
  4. Clinical trajectories from first-line chemotherapy to best supportive care in unresectable pancreatic cancer: a 10-year real-world retrospective study. First author DOI 10.1016/j.ctarc.2026.101409↗
  5. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Co-author DOI 10.1016/j.gie.2026.05.032↗
  6. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  7. Chemotherapy for Unresectable Pancreatic Cancer Complicated by Disseminated Intravascular Coagulation: A Retrospective Cohort Study. Last author DOI 10.1097/mpa.0000000000002707↗
  8. Three-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category, Observed Body Weight, and Prognostic… Last author DOI 10.1177/10966218261457190↗
  9. Longitudinal Changes in Inflammatory and Nutritional Status Are Associated With Survival in Advanced Pancreatic Cancer. First author DOI 10.1177/10966218261500247↗
  10. 6-mm versus 10-mm covered self-expandable metal stents and plastic stents for malignant distal biliary obstruction in resectable or borderline resectable pancr… Co-author DOI 10.1186/s13063-026-09821-1↗
  11. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  12. Covered self-expandable metallic stent versus plastic stent for preoperative endoscopic biliary drainage in patients with pancreatic cancer: a multi-center ret… Co-author DOI 10.1080/00365521.2021.2015802↗
  13. Evaluation of preoperative diagnostic methods for resectable pancreatic cancer: a diagnostic capability and impact on the prognosis of endoscopic ultrasound-gu… Co-author DOI 10.1186/s12876-021-01955-7↗
  14. Endoscopic duodenal stent versus surgical gastrojejunostomy for gastric outlet obstruction in patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.04.015↗
  15. The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer. First author DOI 10.18632/oncotarget.7424↗
  16. The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer. Last author DOI 10.3390/ijms17010137↗
  17. Anticancer effect of arsenite on cell migration, cell cycle and apoptosis in human pancreatic cancer cells. Co-author DOI 10.3892/ol.2016.4564↗
  18. UVC irradiation suppresses platelet-derived growth factor-BB-induced migration in human pancreatic cancer cells. Co-author DOI 10.3892/or.2011.1612↗
  19. Ultraviolet enhances the sensitivity of pancreatic cancer cells to gemcitabine by activation of 5' AMP-activated protein kinase. First author DOI 10.1016/j.bbrc.2011.09.020↗
  20. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2011.09.008↗
  21. Role of EUS in the early detection of small pancreatic cancer. Co-author DOI 10.1111/j.1443-1661.2011.01113.x↗
  22. Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells. Co-author DOI 10.1186/1476-4598-10-79↗
  23. UVC radiation induces downregulation of EGF receptor via phosphorylation at serine 1046/1047 in human pancreatic cancer cells. Co-author DOI 10.1667/rr2445.1↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nobuhiko Hayashi · 7 shared papers, 2026 · strength 1.91
  2. Banri Ogino · 6 shared papers, 2026 · strength 1.58
  3. Shinya Kajiura · 5 shared papers, 2026 · strength 1.33
  4. Kohei Nagata · 4 shared papers, 2026 · strength 1.07
  5. Kazuto Tajiri · 3 shared papers, 2026 · strength 0.81
  6. Shin Hamada · 3 shared papers, 2026 · strength 0.71
  7. Sohei Satoi · 3 shared papers, 2026 · strength 0.71
  8. Shinichi Egawa · 3 shared papers, 2026 · strength 0.71
  9. Kohei Nakata · 3 shared papers, 2026 · strength 0.71
  10. Masamichi Mizuma · 3 shared papers, 2026 · strength 0.71
  11. Yoshifumi Takeyama · 3 shared papers, 2026 · strength 0.71
  12. Michiaki Unno · 3 shared papers, 2026 · strength 0.71
  13. Atsushi Masamune · 3 shared papers, 2026 · strength 0.71
  14. Takao Itoi · 3 shared papers, 2026 · strength 0.71
  15. Ken Shirabe · 3 shared papers, 2026 · strength 0.71
  16. Masahito Shimizu · 6 shared papers, 2016–2022 · strength 0.56
  17. Yuzo Kodama · 2 shared papers, 2026 · strength 0.48
  18. Manabu Kawai · 2 shared papers, 2026 · strength 0.47
  19. Kazuichi Okazaki · 2 shared papers, 2026 · strength 0.47
  20. Takuji Iwashita · 5 shared papers, 2011–2022 · strength 0.45
  21. Shinya Uemura · 3 shared papers, 2018–2022 · strength 0.37
  22. Susumu Hijioka · 1 shared paper, 2026 · strength 0.33
  23. Daiki Yamashige · 1 shared paper, 2026 · strength 0.33
  24. Junji Furuse · 1 shared paper, 2026 · strength 0.33
  25. Makoto Ueno · 1 shared paper, 2026 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.